Search Results

Navigate BioPharma Services, Inc. announces a strategic collaboration with BD (Becton, Dickinson and Company) to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

STERIS plc announced that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company for $540 million.

BD (Becton, Dickinson and Company) announced today that it plans to host webcasts to discuss quarterly financial results on the following dates.

BD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.

Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, announced the appointment of life science leader Todd Dickinson to the Board of Directors.

Galapagos NV announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 11:00 am Eastern Time.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, “AGILITY,” which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD).